Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

International Journal of Clinical Practice
M H DavidsonEzetimibe Study Group

Abstract

We assessed pooled safety and lipid-regulating efficacy data from four similarly designed trials of ezetimibe coadministered with statins in 2382 patients with primary hypercholesterolemia. Patients were randomised to one of the following double-blind treatments for 12 weeks: placebo; ezetimibe 10 mg; statin; or statin + ezetimibe. Statin doses tested were 10, 20, 40 mg/day (atorvastatin, simvastatin, pravastatin or lovastatin) or 80 mg/day (atorvastatin, simvastatin). Treatment with ezetimibe + statin led to significantly greater reductions in low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B and increases in HDL-C, compared to statin alone. At each statin dose, treatment with ezetimibe + statin led to a greater LDL-C reduction compared to the next highest statin monotherapy dose. Ezetimibe + statin had a safety profile similar to statin monotherapy. Coadministration of ezetimibe + statin offers a well-tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia.

References

Nov 24, 1998·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·H E Bays, C A Dujovne
Aug 12, 1999·The New England Journal of Medicine·R H Knopp
Jan 5, 2000·The New England Journal of Medicine·J DornC Galletti
Jun 20, 2000·The American Journal of Cardiology·K G Tolman
Jul 6, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M UcarR Dahlqvist
Sep 8, 2000·Clinical Pharmacology and Therapeutics·J T BackmanP J Neuvonen
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·J A Farmer, G Torre-Amione
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Nov 13, 2001·Southern Medical Journal·D G FedermanA B Walters
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group

❮ Previous
Next ❯

Citations

Jan 16, 2007·Digestive Diseases and Sciences·Qiang LiuLydia M Petrovic
Jun 10, 2010·Advances in Therapy·Abhaya GuptaPhyo Kyaw Myint
Jul 5, 2005·The American Journal of Cardiology·Gilbert R Thompson
Jan 5, 2008·International Journal of Clinical Practice·M FlorentinM S Elisaf
Oct 17, 2007·Annual Review of Medicine·Helene Glassberg, Daniel J Rader
Jan 16, 2010·Journal of Atherosclerosis and Thrombosis·Shinya HiramitsuYukio Ozaki
Jul 23, 2013·Indian Journal of Endocrinology and Metabolism·Sheelu S SiddiqiAsad U Khan
Oct 28, 2008·Current Cardiology Reports·Jennifer G Robinson
Jun 1, 2010·Expert Opinion on Pharmacotherapy·Konstantinos ToutouzasChristodoulos Stefanadis
Mar 23, 2011·Expert Opinion on Drug Safety·Michel Farnier
Apr 1, 2006·Current Medical Research and Opinion·Stella S Daskalopoulou, Dimitri P Mikhailidis
Oct 7, 2006·Current Medical Research and Opinion·Alberico L CatapanoAndrew M Tershakovec
Sep 11, 2009·Current Medical Research and Opinion·I MigdalisD P Mikhailidis
Dec 3, 2010·Journal of Clinical Lipidology·Maurizio AvernaGian Franco Gensini
Feb 16, 2010·European Journal of Pharmacology·Michalis KalogirouMoses Elisaf
May 1, 2009·Journal of Clinical Lipidology·Joseph P Vande Griend, Joseph J Saseen
Feb 17, 2009·Endocrinology and Metabolism Clinics of North America·Evan A Stein
May 21, 2008·The American Journal of Cardiology·Amir KashaniJoAnne M Foody
May 25, 2005·Journal of Internal Medicine·B H R WolffenbuttelUNKNOWN Dutch Corall Study Group
May 7, 2005·International Journal of Clinical Practice. Supplement·E DohertyA S Wierzbicki
Apr 28, 2007·European Journal of Clinical Investigation·F ChenotO S Descamps
Aug 4, 2007·The Journal of Clinical Hypertension·Jordan Asher, Mark Houston
Mar 21, 2007·The American Journal of Cardiology·Terry A JacobsonJohn R Guyton

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.